FY2025 EPS Estimates for Rezolute Boosted by HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – Analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Rezolute in a research note issued on Thursday, May 15th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.91) for the year, up from their previous estimate of ($0.96). HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($1.14) EPS, FY2028 earnings at ($0.59) EPS and FY2029 earnings at ($0.40) EPS.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05).

A number of other equities research analysts have also recently commented on the company. JMP Securities lifted their target price on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 13th. Wedbush restated an “outperform” rating and issued a $12.00 price objective on shares of Rezolute in a research note on Wednesday, May 14th. Guggenheim restated a “buy” rating on shares of Rezolute in a research note on Monday, February 10th. Finally, Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $12.14.

Rezolute Price Performance

RZLT opened at $3.95 on Monday. The company has a market capitalization of $239.11 million, a price-to-earnings ratio of -3.24 and a beta of 1.01. Rezolute has a 1 year low of $2.22 and a 1 year high of $6.19. The firm’s fifty day moving average price is $3.24 and its two-hundred day moving average price is $4.28.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Jeppson Wealth Management LLC bought a new position in shares of Rezolute in the first quarter worth about $35,000. JPMorgan Chase & Co. bought a new stake in Rezolute during the 3rd quarter valued at approximately $42,000. Paloma Partners Management Co bought a new stake in Rezolute during the 1st quarter valued at approximately $48,000. Alpine Global Management LLC bought a new stake in Rezolute during the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd bought a new stake in Rezolute during the 1st quarter valued at approximately $95,000. 82.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Daron Evans bought 10,000 shares of the business’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $2.89 per share, with a total value of $28,900.00. Following the completion of the purchase, the chief financial officer now owns 237,900 shares in the company, valued at approximately $687,531. The trade was a 4.39% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Nevan C. Elam acquired 12,302 shares of the company’s stock in a transaction that occurred on Thursday, March 27th. The shares were acquired at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the transaction, the chief executive officer now directly owns 224,119 shares of the company’s stock, valued at $638,739.15. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 29,060 shares of company stock worth $83,694. 18.39% of the stock is owned by corporate insiders.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.